@charlesmowbray
Drug discovery and development for neglected patients suffering from infectious diseases including leishmaniasis, Chagas disease and viral infections @DNDi in Geneva Posts on LinkedIn at https://www.linkedin.com/in/charlesmowbray/
Beni survived #SleepingSickness thanks to timely diagnosis & innovative oral treatments.
This #WorldChildrensDay we call for support to develop urgently needed life-saving treatments for children like Beni living with NTDs.
Watch his story in our new film www.youtube.com/watch?v=GcIx...
JUST RELEASED: Open science in a closed world 🌍📘Our new policy report shows how open, collaborative science and pro-access IP approaches can accelerate medical innovation & equitable access to health tools for all. #MakeScienceOpen youtube.com/shorts/UmBAr...
Are you going to #ECTMIH2025 in Hamburg next week?
Our team will be speaking about epidemic and pandemic-prone viruses, neglected tropical diseases #NTDs & female genital #schistosomiasis.
👉Find out more: dndi.org/events/2025/...
#beatNTDs
This open science project has been designed from the outset to ensure equitable, affordable global access for anyone in need.
I am incredibly impressed and proud of the work of our team and many collaborators in bringing forward this exciting new preclinical candidate as a contribution to building pandemic preparedness. Congratulations to everyone who has contributed to and supported this program!
Great news! 🎉
Following an independent expert review, we have formally nominated the broad-spectrum pan-coronavirus antiviral ASAP-0017445 as a pre-clinical drug candidate.
🔗Read the press release here: dndi.org/press-releas...
🎉 Our annual report is out! In 2024, we advanced work on 🔬 32 projects, including 16 clinical trials in 7 disease areas, conducted across 🌍 60 sites in 23 countries.
Browse our report to learn how solidarity in science is benefiting the most neglected 👉 bit.ly/4eRbJfq
The @ec.europa.eu’s new Medical Countermeasures Strategy could be a critical tool to support end-to-end R&D specifically as it will support pandemic-prone diseases such as Ebola or dengue. [1/4] 👇
@charlesmowbray.bsky.social @rachaelcrockett.bsky.social @childsmichelle.bsky.social
Exciting and important opportunity for early-career researchers to apply for michelsonprizes.smapply.org for disruptive concepts and inventive processes to advance human immunology, vaccine discovery, and immunotherapy research for major global diseases.
⏰ Only 10 days to go! Apply now to become our next #PatientRepresentative.
We’re looking for someone who can help ensure our programmes and commitments truly reflect the needs of the communities we serve.
📆 4 May 2025
👉 bit.ly/4jvtTVE
📣 Help us spread the word!
We're looking for a new #PatientRepresentative to join our Board and help align our programmes and commitments with the needs of the communities we serve.
🗓️ Apply by 4 May 2025
🔗 Details: bit.ly/dndi-patient...
#PatientCentricity #PatientAdvocacy #GlobalHealth #JoinUs
@drluispizarro.bsky.social
Did you know that we can manage patents in a way that serves the public good?
Our Intellectual Property & Access Leader shares why, together with our partners from the @asapdiscovery.bsky.social, we are filing a #patent for a promising new #molecule that we developed together.
shorturl.at/IgL80
'We want wide, fast, and affordable access for our new antiviral. It might sound counterintuitive, but a patent will help us do that.'
Read our full opinion piece co-authored by Ed Griffen (@griffen-ed.bsky.social) and Pascale Boulet ⤵️
cen.acs.org/pharmaceutic...
Interested in how drugs are discovered? My colleague Fanny Beltran Escudié is explaining more in the latest episode of our Drug Discovery Explained series. Over to you Fanny Beltran Escudié... youtu.be/qAg0osQQqVQ @dndi.org
Listening to the excellent panelists and looking forward to joining the discussion in the workshop later. Its great to have a strong focus on the needs and challenges for pandemic preparedness in Africa and listening to African leaders such as Kelly Chibale.
@dndi.org @ippsecretariat.org
Climate-sensitive infectious diseases are rising, hitting those with the least access to testing and treatment the hardest. We need science-driven solutions to #EndTheNeglect and ensure no one is left behind. 🌍
🔗 dndi.org/advocacy/con...
#WorldNTDDay #BeatNTDs
Today, we spotlight #FGS, an #NTD caused by a parasitic worm 🪱
In Dec, we decided to start conducting research for this disease, recognizing the urgent need for better treatment.
🔗For more info, see the full carousel here: www.instagram.com/p/DFaaKpzoRs...
#WorldNTDDay #BeatNTDs #EndTheNeglect
An inspiring meeting with the LCI in Hamburg this week provides the perfect lead-in to World NTD Day tomorrow!
#WorldNTDDay #EndTheNeglect #beatNTD
@dndi.org
You can find out more at @dndi.org
Innovation is key to eliminating neglected tropical diseases (NTDs). This #WorldNTDDay, we’re
joining @DNDi to invest in solutions that bring treatments, diagnostics, and hope to affected
communities. #EndTheNeglect #beatNTDs
It is great to have @wellcometrust.bsky.social leadership and partnership in this important work!
and watch a short video by my colleague Fanny Beltran Escudié explaining the concept: Host-Directed Therapies: Drugs that target the human body – NOT the cause of illness?
www.youtube.com/watch?v=P2Xl...
You can find an introduction to this topic in our series: Drug discovery explained: What are host-directed therapies? dndi.org/stories/2024...
Leishmaniasis is one of the diseases where @dndi.org and our partners are exploring the role of Host Directed Therapies. We aim to compliment direct acting antiparasitic and antiviral drugs in tackling complex neglected infectious diseases which affect >1bn people.
www.linkedin.com/posts/charle...
www3.nhk.or.jp/nhkworld/en/...
Very happy to raise awareness of the needs of >1bn people affected by terrible neglected diseases such as #Dengue and to highlight the exciting work we have been doing with our colleagues at #BenevolentAI.
Dengue item is at minutes 9:00-12:30 in AI story from 7:30
